Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.

Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.

AIM:To assess the prognostic value of multiple recurrences on the risk of progression in a large cohort of TaG1 bladder cancer of low and intermediate risk based on the EORTC score and to evaluate prognostic factors of multiple recurrences. MATERIALS AND METHODS:We retrospectively analyzed a French...

Full description

Bibliographic Details
Main Authors:	Marie Simon, Pierre-Olivier Bosset, Mathieu Rouanne, Simone Benhamou, Camelia Radulescu, Vincent Molinié, Yann Neuzillet, Xavier Paoletti, Thierry Lebret
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0211721

Similar Items

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables
by: J Fernandez-Gomez, et al.
Published: (2011-10-01)

Incidence of neonatal hyperbilirubinemia in low, intermediate-low, and intermediate-high risk group infants
by: Ahmed Widiasta, et al.
Published: (2016-10-01)

External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1
by: Gilberto L. Almeida, et al.

Expanding TAVI to Low and Intermediate Risk Patients
by: Lisa Voigtländer, et al.
Published: (2018-07-01)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
by: Hiroaki Kunogi, et al.
Published: (2020-12-01)

Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
by: Dana M. Hartl, et al.
Published: (2020-11-01)

Mechanisms of Resistance to BCG Immunotherapy in Bladder Cancer
by: Rouanne, Mathieu
Published: (2019)

Do Standardised Prognostic Algorithms Reflect Local Practice? Application of EORTC Risk Tables for Non-Muscle Invasive (pTa/pT1) Bladder Cancer Recurrence and Progression in a Local Cohort
by: Rajiv Pillai, et al.
Published: (2011-01-01)

Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
by: Khoshnevisan Alireza, et al.
Published: (2012-05-01)

Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder
by: Andreas Bohle
Published: (2010-08-01)

Effects of overexpressing TaGS1/TaGS2 on tobacco salt tolerance and its mechanism
by: JIA Xiting, et al.
Published: (2017-10-01)

Measuring Prostate Cancer Quality of Life:Psychometric Properties of the EORTC-C30 and EORTC-PR25
by: Yu-Jun Chang, et al.
Published: (2008)

Stereotactic body radiation therapy for low- and low-intermediate risk prostate cancer: Is there a dose effect?
by: Alan Jay Katz, et al.
Published: (2011-12-01)

A review of new hormonal therapies for prostate cancer in black men: is there enough data?
by: Matthias E. Meunier, et al.
Published: (2021-01-01)

Screening with Magnetic Resonance Imaging in women at low and intermediate risk of breast Cancer
by: Huzarski T T, et al.
Published: (2012-12-01)

Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy
by: Yann Neuzillet, et al.
Published: (2021-01-01)

Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy
by: Yann Neuzillet, et al.
Published: (2021-01-01)

Re: Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
by: Maurizio Brausi, et al.
Published: (2015-03-01)

Validity, reliability and understanding of the EORTC-C30 and EORTC-BR23, quality of life questionnaires specific for breast cancer
by: Fernanda Alessandra Silva Michels, et al.
Published: (2013-06-01)

Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer
by: Mathieu Rouanne, et al.
Published: (2020-09-01)

A 4-Gene Signature Associated With Recurrence in Low- and Intermediate-Risk Endometrial Cancer
by: Diocésio Alves Pinto de Andrade, et al.
Published: (2021-08-01)

Myocardial remodeling in NSTEMI patients with intermediate and low cardiovascular risk exposed to delayed revascularization
by: Artiom Surev, et al.
Published: (2021-06-01)

Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.
by: Diocesio Alves Pinto de Andrade, et al.
Published: (2019-01-01)

Coronary atherosclerotic burden in veteran male recreational athletes with low to intermediate cardiovascular risk
by: Hélder Dores, et al.
Published: (2020-10-01)

Coronary atherosclerotic burden in veteran male recreational athletes with low to intermediate cardiovascular risk
by: Hélder Dores, et al.
Published: (2020-10-01)

Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis
by: Ana María Gómez-Pérez, et al.
Published: (2020-02-01)

Comparison of the EORTC and CUETO prognostic models in non-muscle-invasive bladder cancer
by: A. D. Kaprin, et al.
Published: (2018-07-01)

Author Correction: Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer
by: Mathieu Rouanne, et al.
Published: (2021-03-01)

International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26
by: Monika Sztankay, et al.
Published: (2018-11-01)

IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
by: Yann Neuzillet, et al.
Published: (2017-09-01)

LOW POWER BRACHYTHERAPY IN COMBINED TREATMENT IN PATIENTS WITH INTERMEDIATE RISK OF LOCALIZED PROST ATE CANCER
by: V. A. Biryukov, et al.
Published: (2015-01-01)

Right Ventricular Outflow Doppler Predicts Low Cardiac Index in Intermediate Risk Pulmonary Embolism
by: Yevgeniy Brailovsky DO, MSc, et al.
Published: (2019-11-01)

Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with Type 2 Diabetes
by: Lau Kui-Kai, et al.
Published: (2012-08-01)

Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer
by: Keisei Okamoto, et al.
Published: (2020-02-01)

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
by: Sultan S Alkhateeb, et al.
Published: (2011-01-01)

Nitrogen Supply and Leaf Age Affect the Expression of TaGS1 or TaGS2 Driven by a Constitutive Promoter in Transgenic Tobacco
by: Yihao Wei, et al.
Published: (2018-08-01)

Cross-cultural analyses of the EORTC QLQ-C30
by: Scott, Neil W.
Published: (2007)

Psychometric properties of the EORTC QLQ-C30 in Uganda
by: Allen Naamala, et al.
Published: (2021-04-01)

The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30
by: Helen McTaggart-Cowan, et al.
Published: (2019-04-01)

Quality of life in patients with lung cancer in Taiwan: Validation of a Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-LC13
by: Tseng, Chun-Hua, et al.
Published: (2005)